SERS‐based biosensor for Alzheimer disease evaluation through the fast analysis of human serum

Carlomagno, Cristiano; Cabinio, Monia; Picciolini, Silvia; Gualerzi, Alice; Baglio, Francesca; Bedoni, Marzia

doi:10.1002/jbio.201960033

Cited by 42 publications

(22 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The specific Raman fingerprint was calculated performing the average spectrum of each experimental group and comparing the resultant spectra through subtraction with error dispersion, individuating the significant intensities variations at the ± 0.005 ∆I level (Fig. 2 a–c) 53 . The single spectra classification model was created and trained using the MVA approach, consisting in consecutive PCA and LDA on the created Raman database, using the whole collected spectra.…”

Section: Methodsmentioning

confidence: 99%

COVID-19 salivary Raman fingerprint: innovative approach for the detection of current and past SARS-CoV-2 infections

Carlomagno

Bertazioli

Gualerzi

et al. 2021

Sci Rep

Self Cite

117

119

View full text Add to dashboard Cite

The pandemic of COVID-19 is continuously spreading, becoming a worldwide emergency. Early and fast identification of subjects with a current or past infection must be achieved to slow down the epidemiological widening. Here we report a Raman-based approach for the analysis of saliva, able to significantly discriminate the signal of patients with a current infection by COVID-19 from healthy subjects and/or subjects with a past infection. Our results demonstrated the differences in saliva biochemical composition of the three experimental groups, with modifications grouped in specific attributable spectral regions. The Raman-based classification model was able to discriminate the signal collected from COVID-19 patients with accuracy, precision, sensitivity and specificity of more than 95%. In order to translate this discrimination from the signal-level to the patient-level, we developed a Deep Learning model obtaining accuracy in the range 89–92%. These findings have implications for the creation of a potential Raman-based diagnostic tool, using saliva as minimal invasive and highly informative biofluid, demonstrating the efficacy of the classification model.

show abstract

Section: Methodsmentioning

confidence: 99%

COVID-19 salivary Raman fingerprint: innovative approach for the detection of current and past SARS-CoV-2 infections

Carlomagno

Bertazioli

Gualerzi

et al. 2021

Sci Rep

Self Cite

117

119

View full text Add to dashboard Cite

show abstract

“…lected from the two experimental groups, with accuracy, precision, and specificity of 83%, 86%, and 86%, respectively. On the other hand, the authors found a direct relationship between brain tissue degeneration visualized by magnetic resonance imaging (MRI) and the appearance of a specific biochemical pattern from SERS data in serum collected from AD patients, showing that SERS is a potential label-free tool for monitoring AD progression and rehabilitation treatments in a minimally invasive way [89]. Hybrid bionanomaterials, such as DNA-AuNPs conjugates, provide excellent platforms for chemical and biological applications.…”

Section: Sers Biosensors For the Simultaneous Detection Of Aβ And Taumentioning

confidence: 99%

Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease

Oyarzún

Tapia-Arellano

Cabrera

et al. 2021

Sensors

View full text Add to dashboard Cite

Alzheimer’s disease (AD), considered a common type of dementia, is mainly characterized by a progressive loss of memory and cognitive functions. Although its cause is multifactorial, it has been associated with the accumulation of toxic aggregates of the amyloid-β peptide (Aβ) and neurofibrillary tangles (NFTs) of tau protein. At present, the development of highly sensitive, high cost-effective, and non-invasive diagnostic tools for AD remains a challenge. In the last decades, nanomaterials have emerged as an interesting and useful tool in nanomedicine for diagnostics and therapy. In particular, plasmonic nanoparticles are well-known to display unique optical properties derived from their localized surface plasmon resonance (LSPR), allowing their use as transducers in various sensing configurations and enhancing detection sensitivity. Herein, this review focuses on current advances in in vitro sensing techniques such as Surface-enhanced Raman scattering (SERS), Surface-enhanced fluorescence (SEF), colorimetric, and LSPR using plasmonic nanoparticles for improving the sensitivity in the detection of main biomarkers related to AD in body fluids. Additionally, we refer to the use of plasmonic nanoparticles for in vivo imaging studies in AD.

show abstract

“…To this end, various SERS‐based biosensing methods are reported for AD biomarker detection. [ 157 ] Yang et al developed Ag nanogap shells (AgNGSs) as SERS active colloidal NPs for the selective and sensitive multiplexed determination of Aβ 1‐42 and Aβ 1‐40 in blood samples of AD patients. [ 158 ] As shown in Figure 6B, SERS‐based bioselective biosensors were designed and fabricated as a “sandwich” structure with AgNGSs and specific Aβ antibody conjugated on the surface of magnetic beads.…”

Section: Nanodiagnostic Approaches For Admentioning

confidence: 99%

Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders

Hanif

Muhammad

Niu

et al. 2021

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Central nervous system (CNS) disorders feature the progressive and selective loss of normal brain functions. CNS disorders often include an irreversible physiological and anatomical loss of neurons that can lead to dysfunction in various parts of the brain and eventually death. Glioblastoma multiforme (GBM) and neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) are hard to be diagnosed at an early stage for the prevention of disease propagation. Such diagnosis is vital for the timely commencement of actual treatments. Nanotechnology brings new diagnosis hope for CNS disorders as it provides ultrasensitive detection for more specific biomarkers. Herein, the recent progress in techniques development for detecting pathological biomarkers for GBM, AD, and PD is summarized, in particular, the principles that govern the design of these sensors, blood–brain barrier (BBB) dysfunction, and its integrity during disease development. Finally, a perspective on future directions to further advance and improve the early‐stage diagnosis of CNS disorders is presented.

show abstract

SERS‐based biosensor for Alzheimer disease evaluation through the fast analysis of human serum

Cited by 42 publications

References 46 publications

COVID-19 salivary Raman fingerprint: innovative approach for the detection of current and past SARS-CoV-2 infections

COVID-19 salivary Raman fingerprint: innovative approach for the detection of current and past SARS-CoV-2 infections

Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer’s Disease

Nanotechnology‐Based Strategies for Early Diagnosis of Central Nervous System Disorders

Contact Info

Product

Resources

About